Location: Cambridge MA
Cambridge, MA-based H3 Biomedicine (H3B) is a leading company in cancer genomics driven drug discovery, delivering on the promise of precision medicine. The company was launched in 2011 with an unprecedented $200 million in initial funding from Eisai, plus a continued ongoing commitment to fund H3B’s robust discovery pipeline and clinical programs. Now with three clinical stage anti-cancer molecules in active development, H3B is able to uniquely leverage distinct insights from cancer genomics and real-life patient data to advance its projects to clinical proof of concept and beyond. H3B embraces a novel business model in which it collaborates with Eisai, a leading global pharmaceutical company, to create a prolific drug discovery engine and partnership platform.
We are seeking a Research Associate/Sr Research Associate for the Discovery and Translational Oncogenomics group. The individual will be scientifically engaged and highly self-motivated with a very strong work ethic and desire to succeed at developing unique anti-cancer compounds for targeted patient populations. The individual will interact with other team members to design and execute molecular and cell biology experiments aimed at defining the mechanism of action of compounds in appropriate genomic backgrounds that represent potential patient populations. Significant cross-functional collaboration with a talented, dedicated group of scientists will ensure exposure of the individual to diverse aspects of the drug discovery process. As part of the team, the candidate will bear significant responsibility for driving the success of their own project with opportunities to acquire new skills in an innovative and fast-paced environment. The position offers the opportunity to take part in the rapid translation of pre-clinical work to application of compounds in the clinical setting.
Principal Duties and Responsibilities
- Responsible for executing in vitro studies relevant to oncology drug development
- Develop and execute cell biology, in vitro pharmacology studies to evaluate pharmacodynamics, and mechanisms of action of drug candidates
- Work closely with the chemistry and preclinical groups, external collaborators, and contract research organizations (CROs) to design and execute in vivo studies
- Undertake mechanism of action studies using cancer cell models from cell line and primary tumor tissues for drug discovery, translational research and evaluating patient selection hypotheses
- Maintenance of laboratory records, procedures and summaries of data
- Perform laboratory experiments and report data and suggest future work to management and project teams
- BS/MS or equivalent
- Minimum 3-5 years of industrial laboratory experience
- Proven ability to work independently and design experiments, troubleshoot, interpret and report data back to teams
- Experience with viability assays, ELISA, flow cytometry, protein analysis (WB), DNA/RNA analysis (PCR/qRT-PCR) and lentiviral work/stable cell line generation
- Prior in vivo pharmacology experience or a willingness to learn basic in vivo mouse work is a plus
- Flexibility to accommodate to rapidly changing priorities and deadlines
- Strong analytical thinking, high attention to detail, and exceptional organizational skills are critical
- A collaborative, proactive mindset is a must; the successful candidate will be project-oriented rather than task-oriented and will understand both the big picture and the details
- The ability to quickly learn and master new skills is required
- Excellent written and oral communication skills
About H3 Biomedicine Inc.
H3 Biomedicine Inc. is a privately-held, uniquely-structured oncology discovery enterprise whose sole mission is to become a prolific source of new drugs that treat more human cancers with greater success. H3 Biomedicine is applying the expertise of leading scientists to the integration of insights from cancer genomics with innovative capabilities in synthetic chemistry and tumor biology to pursue the most promising current opportunity in cancer therapeutics: patient-based, genomics-driven, small molecule drugs.